Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Immunotech BiopharmHKSE:06978 17 OCF Yield % is -44.99 as of Aug. 13, 2026. GuruFocus rates HKSE:06978 with a GF Score™ of 17/100. The stock has 4 warning signs investors should review. Among 1,409 Biotechnology companies, Immunotech Biopharm ranks worse than 82.33% on this metric.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Immunotech Biopharm OCF Yield % Related Terms
Immunotech Biopharm OCF Yield % Historical Data
* Premium members only.
The historical data trend for Immunotech Biopharm's OCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:06978 vs VRTX, REGN, RVMD: OCF Yield % Comparison
For the Biotechnology subindustry, Immunotech Biopharm's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Immunotech Biopharm OCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Immunotech Biopharm's OCF Yield % distribution charts can be found below:
* The bar in red indicates where Immunotech Biopharm's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Immunotech Biopharm (HKSE:06978) has a OCF Yield % of -44.99 as of Aug. 13, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Immunotech Biopharm and its competitors. According to the industry distribution chart, Immunotech Biopharm ranks #1160 out of 1409 companies in the Biotechnology industry, placing it in the top 82.3%.
Is Immunotech Biopharm's OCF Yield % too high?
Immunotech Biopharm's current OCF Yield % is -44.99. Based on the distribution chart, Immunotech Biopharm ranks #1160 out of 1409 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Immunotech Biopharm has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Immunotech Biopharm's OCF Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Immunotech Biopharm ranks #1160 out of 1409 companies for OCF Yield %. This places Immunotech Biopharm in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Biotechnology company?
A good OCF Yield % depends on the Biotechnology industry context. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Immunotech Biopharm and its competitors. Immunotech Biopharm's current OCF Yield % is -44.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Immunotech Biopharm stock overvalued right now?
Immunotech Biopharm (HKSE:06978) has a current OCF Yield % of -44.99. The current OCF Yield % is -44.99. Immunotech Biopharm's overall GF Score™ is 17/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Immunotech Biopharm (HKSE:06978), the current OCF Yield % is -44.99 as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Immunotech Biopharm Ltd is a cellular immunotherapy biopharmaceutical company in China. The company is focused on the research, development, and commercialization of T-cell immunotherapy. Its product EAL is a multi-target cellular immunotherapy product for the treatment of various types of cancer. Its product pipeline features classes of cellular immunotherapy products, including both non-genetically modified and genetically modified products, as well as both multi-target and single-target products. Its other products include the CAR-T cell series and the TCR-T cell series.
17GF Score
Get the complete analysis for HKSE:06978
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:06978 has been successfully added to your 
